Latest Insider Transactions at Genelux Corp (GNLX)
This section provides a real-time view of insider transactions for Genelux Corp (GNLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GENELUX CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GENELUX CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
33,080
-5.23%
|
$66,160
$2.57 P/Share
|
|
Sep 12
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
31,777
-4.78%
|
$63,554
$2.73 P/Share
|
|
Sep 11
2024
|
James L Tyree |
SELL
Open market or private sale
|
Direct |
1,730
-3.51%
|
$3,460
$2.6 P/Share
|
|
Sep 11
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
31,376
-4.51%
|
$62,752
$2.62 P/Share
|
|
Sep 10
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
20,384
-2.85%
|
$40,768
$2.51 P/Share
|
|
Sep 09
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
23,383
-3.16%
|
$46,766
$2.7 P/Share
|
|
Sep 03
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
42,818
-5.47%
|
$85,636
$2.09 P/Share
|
|
Aug 30
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
142,589
-15.41%
|
$285,178
$2.17 P/Share
|
|
Aug 29
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
107,045
-10.37%
|
$107,045
$1.98 P/Share
|
|
Aug 28
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
15,918
-1.52%
|
$31,836
$2.05 P/Share
|
|
Aug 27
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
51,630
-4.69%
|
$103,260
$2.11 P/Share
|
|
Aug 23
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
40,000
-3.51%
|
$80,000
$2.29 P/Share
|
|
Aug 01
2024
|
John W Smither |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+42.86%
|
-
|
|
Aug 01
2024
|
John Thomas |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+7.25%
|
-
|
|
Aug 01
2024
|
Mary Mirabelli |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+43.19%
|
-
|
|
Aug 01
2024
|
James L Tyree |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+44.53%
|
-
|
|
Jun 24
2024
|
Caroline Jewett Head of Quality |
SELL
Open market or private sale
|
Direct |
4,961
-23.47%
|
$9,922
$2.12 P/Share
|
|
Jun 24
2024
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
5,496
-22.09%
|
$10,992
$2.12 P/Share
|
|
Jun 24
2024
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
6,849
-38.66%
|
$13,698
$2.12 P/Share
|
|
May 29
2024
|
Mary Mirabelli |
BUY
Open market or private purchase
|
Direct |
8,000
+39.1%
|
-
|
|
May 29
2024
|
John Thomas |
BUY
Open market or private purchase
|
Direct |
2,500
+0.53%
|
-
|
|
May 29
2024
|
John W Smither |
BUY
Open market or private purchase
|
Direct |
6,250
+32.18%
|
-
|
|
May 29
2024
|
James L Tyree |
BUY
Open market or private purchase
|
Direct |
6,250
+39.16%
|
-
|
|
May 29
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
31,250
+50.0%
|
-
|
|
May 29
2024
|
Sean Ryder General Counsel |
BUY
Open market or private purchase
|
Direct |
10,000
+48.61%
|
-
|
|
May 29
2024
|
Ralph Smalling Head of Regulatory |
BUY
Open market or private purchase
|
Direct |
1,250
+8.58%
|
-
|
|
May 29
2024
|
Thomas Zindrick President and CEO |
BUY
Open market or private purchase
|
Indirect |
200,000
+50.0%
|
-
|
|
May 29
2024
|
Tony Yu VP, Clinical Trial Operations |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
-
|
|
May 15
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
17,094
-1.48%
|
$51,282
$3.66 P/Share
|
|
May 14
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
15,426
-1.32%
|
$46,278
$3.58 P/Share
|
|
May 13
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
3,446
-0.29%
|
$10,338
$3.62 P/Share
|
|
May 08
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
13,919
-1.17%
|
$41,757
$3.82 P/Share
|
|
May 07
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
6,025
-0.5%
|
$18,075
$3.67 P/Share
|
|
May 01
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
33,061
-2.69%
|
$99,183
$3.3 P/Share
|
|
Apr 30
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
20,535
-1.64%
|
$61,605
$3.12 P/Share
|
|
Apr 29
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
6,403
-0.51%
|
$19,209
$3.25 P/Share
|
|
Apr 24
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
8,064
-0.64%
|
$24,192
$3.5 P/Share
|
|
Apr 23
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
22,000
-1.71%
|
$66,000
$3.49 P/Share
|
|
Apr 22
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
14,331
-1.1%
|
$42,993
$3.53 P/Share
|
|
Apr 17
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
22,737
-1.72%
|
$68,211
$3.71 P/Share
|
|
Apr 16
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
48,683
-3.55%
|
$146,049
$3.53 P/Share
|
|
Mar 14
2024
|
Caroline Jewett Head of Quality |
BUY
Grant, award, or other acquisition
|
Direct |
3,612
+12.24%
|
-
|
|
Mar 14
2024
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,270
+28.93%
|
-
|
|
Mar 14
2024
|
Tony Yu VP, Clinical Trial Operations |
BUY
Grant, award, or other acquisition
|
Direct |
11,557
+39.48%
|
-
|
|
Mar 14
2024
|
Joseph Cappello VP, Pharmaceutical Development |
BUY
Grant, award, or other acquisition
|
Direct |
11,557
+35.55%
|
-
|
|
Mar 14
2024
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
2,107
+10.4%
|
-
|
|
Mar 14
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,852
+9.11%
|
-
|
|
Mar 14
2024
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
26,264
+34.35%
|
-
|
|
Feb 19
2024
|
Caroline Jewett Head of Quality |
BUY
Grant, award, or other acquisition
|
Direct |
1,143
+4.88%
|
-
|
|
Feb 19
2024
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,936
+17.85%
|
-
|